RhoVac ApS | LinkedIn
  • enEnglish
  • svSvenska
  • Home
  • About Us
    ▼
    • About Chosa Oncology
    • Board of Directors
    • Team
    • Vision and strategy
  • Product
    ▼
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Scientific Articles
    • Patents
  • Investors
    ▼
    • Financial Reports
      ▼
      • Chosa Oncology
      • Rhovac
    • Presentations
    • Share Information
    • Event calendar
    • Corporate governance
  • News
    ▲
    • News
    • Subscribe
  • Contact
RhoVac AB - Logotype
  • Home
  • About Us
    • About Chosa Oncology
    • Board of Directors
    • Team
    • Vision and strategy
  • Product
    • iCIP™
    • LiPlaCis®
    • DRP®
    • Scientific Articles
    • Patents
  • Investors
    • Financial Reports
      • Chosa Oncology
      • Rhovac
    • Presentations
    • Share Information
    • Event calendar
    • Corporate governance
  • News
    • News
    • Subscribe
  • Contact
  • RHOVAC 1.27 (-0.02)

News

  • News
  • Subscribe

Jan 18, 2023

RhoVac AB (under name change to Chosa Oncology AB) has completed the acquisition of Chosa ApS and a new board and CEO have taken office

Regulatory press release: RhoVac AB (under name change to Chosa Oncology AB) (“RhoVac or the “Company) has today completed the acquisition of the Danish privately owned oncology company Chosa ApS (“Chosa). As a result, a new...[Read more]

Older news

News published before 2023 >>

Contact

Visiting address: Medicon Village, Scheeletorget 1, Lund, Sweden | Postal address: Medicon Village AB, SE-223 81 Lund, Sweden | Org.no: 559037-2271

+46 73-751 72 78 info@chosa.bio


RhoVac has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 879817.


Cookie Policy © 2015-2023 Chosa Oncology AB All rights reserved